Lyell Immunopharma Stock (NASDAQ:LYEL)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.11

52W Range

$0.85 - $3.26

50D Avg

$1.21

200D Avg

$1.84

Market Cap

$287.60M

Avg Vol (3M)

$1.12M

Beta

-0.48

Div Yield

-

LYEL Company Profile


Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

224

IPO Date

Jun 17, 2021

Website

LYEL Performance


LYEL Financial Summary


Dec 23Dec 22Dec 21
Revenue$130.00K$84.68M$10.65M
Operating Income$-247.01M$-183.12M$-214.78M
Net Income$-234.63M$-4.75M$-285.50M
EBITDA$-213.84M$-165.10M$-164.71M
Basic EPS-$-0.02$-2.10
Diluted EPS-$-0.02$-2.10

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
NUVBNuvation Bio Inc.
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc. Warrant
MRUSMerus N.V.
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
INBXInhibrx Biosciences, Inc.
GBIOGeneration Bio Co.
KRONKronos Bio, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
CCCCC4 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
NKTXNkarta, Inc.
STTKShattuck Labs, Inc.